855 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
TEVA Teva Pharmaceutical Industries Limited $23.43 $23.86B N/A
Article Searches
Teva Pharmaceutical Industries Limited 2016 Q2 - Results - Earnings Call Slides http://seekingalpha.com/article/3996333-teva-pharmaceutical-industries-limited-2016-q2-results-earnings-call-slides?source=feed_tag_israel Aug 05, 2016 - The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with their 2016 Q2 earnings call.
Teva (TEVA) Beats on Q2 Earnings & Revenues, Stock Gains http://www.zacks.com/stock/news/226946/teva-teva-beats-on-q2-earnings-revenues-stock-gains?cid=CS-ZC-FT-226946 Aug 05, 2016 - In addition to reporting better-than-expected results, Teva (TEVA) also closed the Actavis Generics deal and announced it will be acquiring Allergan's Anda business.
Teva Pharmaceutical Industries (TEVA) Erez Vigodman on Q2 2016 Results - Earnings Call Transcript http://seekingalpha.com/article/3995942-teva-pharmaceutical-industries-teva-erez-vigodman-q2-2016-results-earnings-call-transcript?source=feed_tag_israel Aug 04, 2016 - Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)Q2 2016 Earnings CallAugust 04, 2016 8:00 am ETExecutivesKevin C. Mannix - Senior Vice President, Head of Investor RelationsErez Vigodman - President, Ch
Teva Non-GAAP EPS down 13% in Q2; updates guidance http://seekingalpha.com/news/3200086-teva-non-gaap-eps-13-percent-q2-updates-guidance?source=feed_news_all Aug 04, 2016 - Teva Pharmaceutical ([[TEVA]] +0.6%) Q2 results: Revenues: $5,038M (+1.4%); R&D Expense: $375M (-2.8%); SG&A: $1,263M (+6.6%); Operating Income: $361M (-45
Allergan (AGN) Q2 Earnings: Will the Stock Disappoint? http://www.zacks.com/stock/news/226764/allergan-agn-q2-earnings-will-the-stock-disappoint?cid=CS-ZC-FT-226764 Aug 04, 2016 - Allergan's (AGN) Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is a negative 1.49% - will the stock disappoint?
Teva (TEVA) Beats on Q2 Earnings & Revenues http://www.zacks.com/stock/news/226750/teva-teva-beats-on-q2-earnings-revenues?cid=CS-ZC-FT-226750 Aug 04, 2016 - Teva (TEVA) completed the Actavis Generics acquisition earlier this week.
Teva to seek growth beyond $40.5B Allergan deal, CEO says; buys Allergan U.S. distribution unit for $500M http://seekingalpha.com/news/3199288-teva-seek-growth-beyond-40_5b-allergan-deal-ceo-says-buys-allergan-u-s-distribution-unit-500m?source=feed_news_all Aug 03, 2016 - Teva Pharmaceutical ([[TEVA]] +1%) CEO Erex Vigodman tells Bloomberg that the completion of its $40.5B purchase of Allergan's ([[AGN]] +1.6%) generics unit
5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More http://www.zacks.com/stock/news/226539/5-drug-stocks-to-watch-for-earnings-on-aug-4-bmrn-more?cid=CS-ZC-FT-226539 Aug 03, 2016 - How will drug stocks like BMRN, TEVA, REGN and others, scheduled to report on Aug 4, fare this earnings season?
Teva (TEVA): Stock Likely to Beat on Earnings in Q2 Again? http://www.zacks.com/stock/news/226197/teva-teva-stock-likely-to-beat-on-earnings-in-q2-again?cid=CS-ZC-FT-226197 Aug 02, 2016 - Our proven model shows that Teva (TEVA) is likely to beat earnings this quarter because it has the right combination of two key ingredients.
U.S. FTC blesses Teva purchase of Actavis Generics http://seekingalpha.com/news/3196563-u-s-ftc-blesses-teva-purchase-actavis-generics?source=feed_news_all Jul 27, 2016 - The U.S. Federal Trade Commission ((FTC)) accepts the proposed consent order related to Teva Pharmaceutical Industries' ([[TEVA]] +1.4%) acquisition of Act

Pages: 1...77787980818283848586

<<<Page 82>